APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting rhG-CSF

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Long-acting rhG-CSF Market Analysis and Forecast 2026-2032

23 December 2025190 pages

Choose your research edition.

Industry ResearchLong-acting rhG-CSF Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting rhG-CSF Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Long-acting rhG-CSF Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting rhG-CSF Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting rhG-CSF Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Long-acting rhG-CSF market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Long-acting rhG-CSF is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Long-acting rhG-CSF is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Long-acting rhG-CSF is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Long-acting rhG-CSF is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Long-acting rhG-CSF include Yifan Pharmaceutical, CSPC, Sandoz (Novartis), Qilu Pharmaceutical, Mylan, Pfizer, Jiangsu Hengrui Medicine, Fresenius Kabi and Amgen Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Long-acting rhG-CSF, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Long-acting rhG-CSF, also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting rhG-CSF, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-acting rhG-CSF sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Long-acting rhG-CSF market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Long-acting rhG-CSF sales, projected growth trends, production technology, application and end-user industry.

Long-acting rhG-CSF Segment by Company

Yifan Pharmaceutical

CSPC

Sandoz (Novartis)

Qilu Pharmaceutical

Mylan

Pfizer

Jiangsu Hengrui Medicine

Fresenius Kabi

Amgen Inc.

Spectrum Pharmaceuticals

Coherus BioSciences, Inc.

Biocon Biologics Inc.

Long-acting rhG-CSF Segment by Type

Long-acting rhG-CSF

Long-acting PEG-rhG-CSF

Long-acting rhG-CSF Segment by Application

Blood Disorders

Neoplastic Diseases

Others

Long-acting rhG-CSF Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting rhG-CSF market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting rhG-CSF and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting rhG-CSF.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Long-acting rhG-CSF in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Long-acting rhG-CSF manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting rhG-CSF sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Long-acting rhG-CSF Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Long-acting rhG-CSF Major Manufacturers Table 3. Long-acting PEG-rhG-CSF Major Manufacturers Table 4. Global Long-acting rhG-CSF Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Blood Disorders Major Manufacturers Table 6. Neoplastic Diseases Major Manufacturers Table 7. Others Major Manufacturers Table 8. Long-acting rhG-CSF Industry Trends Table 9. Long-acting rhG-CSF Industry Drivers Table 10. Long-acting rhG-CSF Industry Opportunities and Challenges Table 11. Long-acting rhG-CSF Industry Restraints Table 12. Global Long-acting rhG-CSF Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Long-acting rhG-CSF Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Long-acting rhG-CSF Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Long-acting rhG-CSF Revenue Market Share by Region (2021-2026) Table 16. Global Long-acting rhG-CSF Revenue Market Share by Region (2027-2032) Table 17. Global Long-acting rhG-CSF Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (units) Table 18. Global Long-acting rhG-CSF Sales by Region (2021-2026) & (units) Table 19. Global Long-acting rhG-CSF Sales by Region (2027-2032) & (units) Table 20. Global Long-acting rhG-CSF Sales Market Share by Region (2021-2026) Table 21. Global Long-acting rhG-CSF Sales Market Share by Region (2027-2032) Table 22. Global Long-acting rhG-CSF Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Long-acting rhG-CSF Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Long-acting rhG-CSF Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Long-acting rhG-CSF Sales Market Share by Manufacturers (2021-2026) Table 26. Global Long-acting rhG-CSF Sales Price (USD/unit) of Manufacturers (2021-2026) Table 27. Global Long-acting rhG-CSF Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Long-acting rhG-CSF Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Long-acting rhG-CSF Manufacturers, Product Type & Application Table 30. Global Long-acting rhG-CSF Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Long-acting rhG-CSF by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Long-acting rhG-CSF Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Long-acting rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Long-acting rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Long-acting rhG-CSF Revenue Market Share by Type (2021-2026) Table 37. Global Long-acting rhG-CSF Revenue Market Share by Type (2027-2032) Table 38. Global Long-acting rhG-CSF Sales by Type 2021 VS 2025 VS 2032 (units) Table 39. Global Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 40. Global Long-acting rhG-CSF Sales by Type (2027-2032) & (units) Table 41. Global Long-acting rhG-CSF Sales Market Share by Type (2021-2026) Table 42. Global Long-acting rhG-CSF Sales Market Share by Type (2027-2032) Table 43. Global Long-acting rhG-CSF Price by Type (2021-2026) & (USD/unit) Table 44. Global Long-acting rhG-CSF Price by Type (2027-2032) & (USD/unit) Table 45. Global Long-acting rhG-CSF Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Long-acting rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Long-acting rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Long-acting rhG-CSF Revenue Market Share by Application (2021-2026) Table 49. Global Long-acting rhG-CSF Revenue Market Share by Application (2027-2032) Table 50. Global Long-acting rhG-CSF Sales by Application 2021 VS 2025 VS 2032 (units) Table 51. Global Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 52. Global Long-acting rhG-CSF Sales by Application (2027-2032) & (units) Table 53. Global Long-acting rhG-CSF Sales Market Share by Application (2021-2026) Table 54. Global Long-acting rhG-CSF Sales Market Share by Application (2027-2032) Table 55. Global Long-acting rhG-CSF Price by Application (2021-2026) & (USD/unit) Table 56. Global Long-acting rhG-CSF Price by Application (2027-2032) & (USD/unit) Table 57. Yifan Pharmaceutical Company Information Table 58. Yifan Pharmaceutical Business Overview Table 59. Yifan Pharmaceutical Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 60. Yifan Pharmaceutical Long-acting rhG-CSF Product Portfolio Table 61. Yifan Pharmaceutical Recent Development Table 62. CSPC Company Information Table 63. CSPC Business Overview Table 64. CSPC Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 65. CSPC Long-acting rhG-CSF Product Portfolio Table 66. CSPC Recent Development Table 67. Sandoz (Novartis) Company Information Table 68. Sandoz (Novartis) Business Overview Table 69. Sandoz (Novartis) Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 70. Sandoz (Novartis) Long-acting rhG-CSF Product Portfolio Table 71. Sandoz (Novartis) Recent Development Table 72. Qilu Pharmaceutical Company Information Table 73. Qilu Pharmaceutical Business Overview Table 74. Qilu Pharmaceutical Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 75. Qilu Pharmaceutical Long-acting rhG-CSF Product Portfolio Table 76. Qilu Pharmaceutical Recent Development Table 77. Mylan Company Information Table 78. Mylan Business Overview Table 79. Mylan Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 80. Mylan Long-acting rhG-CSF Product Portfolio Table 81. Mylan Recent Development Table 82. Pfizer Company Information Table 83. Pfizer Business Overview Table 84. Pfizer Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 85. Pfizer Long-acting rhG-CSF Product Portfolio Table 86. Pfizer Recent Development Table 87. Jiangsu Hengrui Medicine Company Information Table 88. Jiangsu Hengrui Medicine Business Overview Table 89. Jiangsu Hengrui Medicine Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Jiangsu Hengrui Medicine Long-acting rhG-CSF Product Portfolio Table 91. Jiangsu Hengrui Medicine Recent Development Table 92. Fresenius Kabi Company Information Table 93. Fresenius Kabi Business Overview Table 94. Fresenius Kabi Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Fresenius Kabi Long-acting rhG-CSF Product Portfolio Table 96. Fresenius Kabi Recent Development Table 97. Amgen Inc. Company Information Table 98. Amgen Inc. Business Overview Table 99. Amgen Inc. Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Amgen Inc. Long-acting rhG-CSF Product Portfolio Table 101. Amgen Inc. Recent Development Table 102. Spectrum Pharmaceuticals Company Information Table 103. Spectrum Pharmaceuticals Business Overview Table 104. Spectrum Pharmaceuticals Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Spectrum Pharmaceuticals Long-acting rhG-CSF Product Portfolio Table 106. Spectrum Pharmaceuticals Recent Development Table 107. Coherus BioSciences, Inc. Company Information Table 108. Coherus BioSciences, Inc. Business Overview Table 109. Coherus BioSciences, Inc. Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Coherus BioSciences, Inc. Long-acting rhG-CSF Product Portfolio Table 111. Coherus BioSciences, Inc. Recent Development Table 112. Biocon Biologics Inc. Company Information Table 113. Biocon Biologics Inc. Business Overview Table 114. Biocon Biologics Inc. Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Biocon Biologics Inc. Long-acting rhG-CSF Product Portfolio Table 116. Biocon Biologics Inc. Recent Development Table 117. North America Long-acting rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 118. North America Long-acting rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 119. North America Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 120. North America Long-acting rhG-CSF Sales by Type (2027-2032) & (units) Table 121. North America Long-acting rhG-CSF Sales Price by Type (2021-2026) & (USD/unit) Table 122. North America Long-acting rhG-CSF Sales Price by Type (2027-2032) & (USD/unit) Table 123. North America Long-acting rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 124. North America Long-acting rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 125. North America Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 126. North America Long-acting rhG-CSF Sales by Application (2027-2032) & (units) Table 127. North America Long-acting rhG-CSF Sales Price by Application (2021-2026) & (USD/unit) Table 128. North America Long-acting rhG-CSF Sales Price by Application (2027-2032) & (USD/unit) Table 129. North America Long-acting rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. North America Long-acting rhG-CSF Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 131. North America Long-acting rhG-CSF Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 132. North America Long-acting rhG-CSF Sales by Country (2021 VS 2025 VS 2032) & (units) Table 133. North America Long-acting rhG-CSF Sales by Country (2021-2026) & (units) Table 134. North America Long-acting rhG-CSF Sales by Country (2027-2032) & (units) Table 135. North America Long-acting rhG-CSF Sales Price by Country (2021-2026) & (USD/unit) Table 136. North America Long-acting rhG-CSF Sales Price by Country (2027-2032) & (USD/unit) Table 137. United States Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 138. Canada Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 139. Mexico Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 140. Europe Long-acting rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 141. Europe Long-acting rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 142. Europe Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 143. Europe Long-acting rhG-CSF Sales by Type (2027-2032) & (units) Table 144. Europe Long-acting rhG-CSF Sales Price by Type (2021-2026) & (USD/unit) Table 145. Europe Long-acting rhG-CSF Sales Price by Type (2027-2032) & (USD/unit) Table 146. Europe Long-acting rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 147. Europe Long-acting rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 148. Europe Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 149. Europe Long-acting rhG-CSF Sales by Application (2027-2032) & (units) Table 150. Europe Long-acting rhG-CSF Sales Price by Application (2021-2026) & (USD/unit) Table 151. Europe Long-acting rhG-CSF Sales Price by Application (2027-2032) & (USD/unit) Table 152. Europe Long-acting rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 153. Europe Long-acting rhG-CSF Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 154. Europe Long-acting rhG-CSF Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 155. Europe Long-acting rhG-CSF Sales by Country (2021 VS 2025 VS 2032) & (units) Table 156. Europe Long-acting rhG-CSF Sales by Country (2021-2026) & (units) Table 157. Europe Long-acting rhG-CSF Sales by Country (2027-2032) & (units) Table 158. Europe Long-acting rhG-CSF Sales Price by Country (2021-2026) & (USD/unit) Table 159. Europe Long-acting rhG-CSF Sales Price by Country (2027-2032) & (USD/unit) Table 160. Germany Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 161. France Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 162. U.K. Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 163. Italy Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 164. Russia Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 165. Spain Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 166. Netherlands Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 167. Switzerland Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 168. Sweden Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 169. Poland Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 170. China Long-acting rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 171. China Long-acting rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 172. China Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 173. China Long-acting rhG-CSF Sales by Type (2027-2032) & (units) Table 174. China Long-acting rhG-CSF Sales Price by Type (2021-2026) & (USD/unit) Table 175. China Long-acting rhG-CSF Sales Price by Type (2027-2032) & (USD/unit) Table 176. China Long-acting rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 177. China Long-acting rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 178. China Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 179. China Long-acting rhG-CSF Sales by Application (2027-2032) & (units) Table 180. China Long-acting rhG-CSF Sales Price by Application (2021-2026) & (USD/unit) Table 181. China Long-acting rhG-CSF Sales Price by Application (2027-2032) & (USD/unit) Table 182. Asia Long-acting rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 183. Asia Long-acting rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 184. Asia Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 185. Asia Long-acting rhG-CSF Sales by Type (2027-2032) & (units) Table 186. Asia Long-acting rhG-CSF Sales Price by Type (2021-2026) & (USD/unit) Table 187. Asia Long-acting rhG-CSF Sales Price by Type (2027-2032) & (USD/unit) Table 188. Asia Long-acting rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 189. Asia Long-acting rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 190. Asia Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 191. Asia Long-acting rhG-CSF Sales by Application (2027-2032) & (units) Table 192. Asia Long-acting rhG-CSF Sales Price by Application (2021-2026) & (USD/unit) Table 193. Asia Long-acting rhG-CSF Sales Price by Application (2027-2032) & (USD/unit) Table 194. Asia Long-acting rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 195. Asia Long-acting rhG-CSF Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 196. Asia Long-acting rhG-CSF Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 197. Asia Long-acting rhG-CSF Sales by Country (2021 VS 2025 VS 2032) & (units) Table 198. Asia Long-acting rhG-CSF Sales by Country (2021-2026) & (units) Table 199. Asia Long-acting rhG-CSF Sales by Country (2027-2032) & (units) Table 200. Asia Long-acting rhG-CSF Sales Price by Country (2021-2026) & (USD/unit) Table 201. Asia Long-acting rhG-CSF Sales Price by Country (2027-2032) & (USD/unit) Table 202. Japan Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 203. South Korea Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 204. India Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 205. Australia Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 206. Taiwan Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 207. Southeast Asia Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 208. SAMEA Long-acting rhG-CSF Revenue by Type (2021-2026) & (US$ Million) Table 209. SAMEA Long-acting rhG-CSF Revenue by Type (2027-2032) & (US$ Million) Table 210. SAMEA Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 211. SAMEA Long-acting rhG-CSF Sales by Type (2027-2032) & (units) Table 212. SAMEA Long-acting rhG-CSF Sales Price by Type (2021-2026) & (USD/unit) Table 213. SAMEA Long-acting rhG-CSF Sales Price by Type (2027-2032) & (USD/unit) Table 214. SAMEA Long-acting rhG-CSF Revenue by Application (2021-2026) & (US$ Million) Table 215. SAMEA Long-acting rhG-CSF Revenue by Application (2027-2032) & (US$ Million) Table 216. SAMEA Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 217. SAMEA Long-acting rhG-CSF Sales by Application (2027-2032) & (units) Table 218. SAMEA Long-acting rhG-CSF Sales Price by Application (2021-2026) & (USD/unit) Table 219. SAMEA Long-acting rhG-CSF Sales Price by Application (2027-2032) & (USD/unit) Table 220. SAMEA Long-acting rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 221. SAMEA Long-acting rhG-CSF Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 222. SAMEA Long-acting rhG-CSF Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 223. SAMEA Long-acting rhG-CSF Sales by Country (2021 VS 2025 VS 2032) & (units) Table 224. SAMEA Long-acting rhG-CSF Sales by Country (2021-2026) & (units) Table 225. SAMEA Long-acting rhG-CSF Sales by Country (2027-2032) & (units) Table 226. SAMEA Long-acting rhG-CSF Sales Price by Country (2021-2026) & (USD/unit) Table 227. SAMEA Long-acting rhG-CSF Sales Price by Country (2027-2032) & (USD/unit) Table 228. Brazil Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 229. Argentina Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 230. Chile Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 231. Colombia Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 232. Peru Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 233. Saudi Arabia Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 234. Israel Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 235. UAE Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 236. Turkey Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 237. Iran Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 238. Egypt Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Table 239. Key Raw Materials Table 240. Raw Materials Key Suppliers Table 241. Long-acting rhG-CSF Distributors List Table 242. Long-acting rhG-CSF Customers List Table 243. Research Programs/Design for This Report Table 244. Authors List of This Report Table 245. Secondary Sources Table 246. Primary Sources List of Figures Figure 1. Long-acting rhG-CSF Image Figure 2. Global Long-acting rhG-CSF Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting rhG-CSF Market Size Share 2021 VS 2025 VS 2032 Figure 4. Long-acting rhG-CSF Image Figure 5. Long-acting PEG-rhG-CSF Image Figure 6. Global Long-acting rhG-CSF Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Long-acting rhG-CSF Market Size Share 2021 VS 2025 VS 2032 Figure 8. Blood Disorders Image Figure 9. Neoplastic Diseases Image Figure 10. Others Image Figure 11. Global Long-acting rhG-CSF Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Long-acting rhG-CSF Revenue (2021-2032) & (US$ Million) Figure 13. Global Long-acting rhG-CSF Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Long-acting rhG-CSF Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Long-acting rhG-CSF Revenue Market Share by Region (2021-2032) Figure 16. Global Long-acting rhG-CSF Sales (2021-2032) & (units) Figure 17. Global Long-acting rhG-CSF Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 18. Global Long-acting rhG-CSF Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Long-acting rhG-CSF Sales YoY (2021-2032) & (units) Figure 20. Europe Long-acting rhG-CSF Sales YoY (2021-2032) & (units) Figure 21. China Long-acting rhG-CSF Sales YoY (2021-2032) & (units) Figure 22. Asia (Excluding China) Long-acting rhG-CSF Sales YoY (2021-2032) & (units) Figure 23. South America, Middle East and Africa Long-acting rhG-CSF Sales YoY (2021-2032) & (units) Figure 24. Global Long-acting rhG-CSF Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Long-acting rhG-CSF Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Long-acting rhG-CSF Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Long-acting rhG-CSF Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Long-acting rhG-CSF Revenue Market Share by Type (2021-2032) Figure 30. Global Long-acting rhG-CSF Sales by Type (2021 VS 2025 VS 2032) & (units) Figure 31. Global Long-acting rhG-CSF Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Long-acting rhG-CSF Sales Market Share by Type (2021-2032) Figure 33. Global Long-acting rhG-CSF Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Long-acting rhG-CSF Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Long-acting rhG-CSF Revenue Market Share by Application (2021-2032) Figure 36. Global Long-acting rhG-CSF Sales by Application (2021 VS 2025 VS 2032) & (units) Figure 37. Global Long-acting rhG-CSF Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Long-acting rhG-CSF Sales Market Share by Application (2021-2032) Figure 39. North America Long-acting rhG-CSF Revenue Share by Type (2021-2032) Figure 40. North America Long-acting rhG-CSF Sales Share by Type (2021-2032) Figure 41. North America Long-acting rhG-CSF Revenue Share by Application (2021-2032) Figure 42. North America Long-acting rhG-CSF Sales Share by Application (2021-2032) Figure 43. North America Long-acting rhG-CSF Revenue Share by Country (2021-2032) Figure 44. North America Long-acting rhG-CSF Sales Share by Country (2021-2032) Figure 45. Europe Long-acting rhG-CSF Revenue Share by Type (2021-2032) Figure 46. Europe Long-acting rhG-CSF Sales Share by Type (2021-2032) Figure 47. Europe Long-acting rhG-CSF Revenue Share by Application (2021-2032) Figure 48. Europe Long-acting rhG-CSF Sales Share by Application (2021-2032) Figure 49. Europe Long-acting rhG-CSF Revenue Share by Country (2021-2032) Figure 50. Europe Long-acting rhG-CSF Sales Share by Country (2021-2032) Figure 51. China Long-acting rhG-CSF Revenue Share by Type (2021-2032) Figure 52. China Long-acting rhG-CSF Sales Share by Type (2021-2032) Figure 53. China Long-acting rhG-CSF Revenue Share by Application (2021-2032) Figure 54. China Long-acting rhG-CSF Sales Share by Application (2021-2032) Figure 55. Asia Long-acting rhG-CSF Revenue Share by Type (2021-2032) Figure 56. Asia Long-acting rhG-CSF Sales Share by Type (2021-2032) Figure 57. Asia Long-acting rhG-CSF Revenue Share by Application (2021-2032) Figure 58. Asia Long-acting rhG-CSF Sales Share by Application (2021-2032) Figure 59. Asia Long-acting rhG-CSF Revenue Share by Country (2021-2032) Figure 60. Asia Long-acting rhG-CSF Sales Share by Country (2021-2032) Figure 61. SAMEA Long-acting rhG-CSF Revenue Share by Type (2021-2032) Figure 62. SAMEA Long-acting rhG-CSF Sales Share by Type (2021-2032) Figure 63. SAMEA Long-acting rhG-CSF Revenue Share by Application (2021-2032) Figure 64. SAMEA Long-acting rhG-CSF Sales Share by Application (2021-2032) Figure 65. SAMEA Long-acting rhG-CSF Revenue Share by Country (2021-2032) Figure 66. SAMEA Long-acting rhG-CSF Sales Share by Country (2021-2032) Figure 67. Long-acting rhG-CSF Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Long-acting rhG-CSF Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Long-acting rhG-CSF
  • Long-acting PEG-rhG-CSF
Applications
  • Blood Disorders
  • Neoplastic Diseases
  • Others
Companies covered
  • Yifan Pharmaceutical
  • CSPC
  • Sandoz (Novartis)
  • Qilu Pharmaceutical
  • Mylan
  • Pfizer
  • Jiangsu Hengrui Medicine
  • Fresenius Kabi
  • Amgen Inc.
  • Spectrum Pharmaceuticals
  • Coherus BioSciences, Inc.
  • Biocon Biologics Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Long-acting rhG-CSF Market by Type
  3. 1.2.1 Global Long-acting rhG-CSF Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Long-acting rhG-CSF
  5. 1.2.3 Long-acting PEG-rhG-CSF
  6. 1.3 Long-acting rhG-CSF Market by Application
  7. 1.3.1 Global Long-acting rhG-CSF Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Blood Disorders
  9. 1.3.3 Neoplastic Diseases
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Long-acting rhG-CSF Market Dynamics
  1. 2.1 Long-acting rhG-CSF Industry Trends
  2. 2.2 Long-acting rhG-CSF Industry Drivers
  3. 2.3 Long-acting rhG-CSF Industry Opportunities and Challenges
  4. 2.4 Long-acting rhG-CSF Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Long-acting rhG-CSF Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Long-acting rhG-CSF Revenue by Region
  3. 3.2.1 Global Long-acting rhG-CSF Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Long-acting rhG-CSF Revenue by Region (2021-2026)
  5. 3.2.3 Global Long-acting rhG-CSF Revenue by Region (2027-2032)
  6. 3.2.4 Global Long-acting rhG-CSF Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Long-acting rhG-CSF Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Long-acting rhG-CSF Sales by Region
  9. 3.4.1 Global Long-acting rhG-CSF Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Long-acting rhG-CSF Sales by Region (2021-2026)
  11. 3.4.3 Global Long-acting rhG-CSF Sales by Region (2027-2032)
  12. 3.4.4 Global Long-acting rhG-CSF Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Long-acting rhG-CSF Revenue by Manufacturers
  2. 4.1.1 Global Long-acting rhG-CSF Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Long-acting rhG-CSF Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Long-acting rhG-CSF Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Long-acting rhG-CSF Sales by Manufacturers
  6. 4.2.1 Global Long-acting rhG-CSF Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Long-acting rhG-CSF Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Long-acting rhG-CSF Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Long-acting rhG-CSF Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Long-acting rhG-CSF Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Long-acting rhG-CSF Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Long-acting rhG-CSF Manufacturers, Product Type & Application
  13. 4.7 Global Long-acting rhG-CSF Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Long-acting rhG-CSF Market CR5 and HHI
  16. 4.8.2 2025 Long-acting rhG-CSF Tier 1, Tier 2, and Tier 3
5 Long-acting rhG-CSF Market by Type
  1. 5.1 Global Long-acting rhG-CSF Revenue by Type
  2. 5.1.1 Global Long-acting rhG-CSF Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Long-acting rhG-CSF Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Long-acting rhG-CSF Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Long-acting rhG-CSF Sales by Type
  6. 5.2.1 Global Long-acting rhG-CSF Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting rhG-CSF Sales by Type (2021-2032) & (units)
  8. 5.2.3 Global Long-acting rhG-CSF Sales Market Share by Type (2021-2032)
  9. 5.3 Global Long-acting rhG-CSF Price by Type
6 Long-acting rhG-CSF Market by Application
  1. 6.1 Global Long-acting rhG-CSF Revenue by Application
  2. 6.1.1 Global Long-acting rhG-CSF Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Long-acting rhG-CSF Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Long-acting rhG-CSF Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Long-acting rhG-CSF Sales by Application
  6. 6.2.1 Global Long-acting rhG-CSF Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Long-acting rhG-CSF Sales by Application (2021-2032) & (units)
  8. 6.2.3 Global Long-acting rhG-CSF Sales Market Share by Application (2021-2032)
  9. 6.3 Global Long-acting rhG-CSF Price by Application
7 Company Profiles
  1. 7.1 Yifan Pharmaceutical
  2. 7.1.1 Yifan Pharmaceutical Company Information
  3. 7.1.2 Yifan Pharmaceutical Business Overview
  4. 7.1.3 Yifan Pharmaceutical Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Yifan Pharmaceutical Long-acting rhG-CSF Product Portfolio
  6. 7.1.5 Yifan Pharmaceutical Recent Developments
  7. 7.2 CSPC
  8. 7.2.1 CSPC Company Information
  9. 7.2.2 CSPC Business Overview
  10. 7.2.3 CSPC Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 CSPC Long-acting rhG-CSF Product Portfolio
  12. 7.2.5 CSPC Recent Developments
  13. 7.3 Sandoz (Novartis)
  14. 7.3.1 Sandoz (Novartis) Company Information
  15. 7.3.2 Sandoz (Novartis) Business Overview
  16. 7.3.3 Sandoz (Novartis) Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sandoz (Novartis) Long-acting rhG-CSF Product Portfolio
  18. 7.3.5 Sandoz (Novartis) Recent Developments
  19. 7.4 Qilu Pharmaceutical
  20. 7.4.1 Qilu Pharmaceutical Company Information
  21. 7.4.2 Qilu Pharmaceutical Business Overview
  22. 7.4.3 Qilu Pharmaceutical Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Qilu Pharmaceutical Long-acting rhG-CSF Product Portfolio
  24. 7.4.5 Qilu Pharmaceutical Recent Developments
  25. 7.5 Mylan
  26. 7.5.1 Mylan Company Information
  27. 7.5.2 Mylan Business Overview
  28. 7.5.3 Mylan Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Mylan Long-acting rhG-CSF Product Portfolio
  30. 7.5.5 Mylan Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Long-acting rhG-CSF Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 Jiangsu Hengrui Medicine
  38. 7.7.1 Jiangsu Hengrui Medicine Company Information
  39. 7.7.2 Jiangsu Hengrui Medicine Business Overview
  40. 7.7.3 Jiangsu Hengrui Medicine Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Jiangsu Hengrui Medicine Long-acting rhG-CSF Product Portfolio
  42. 7.7.5 Jiangsu Hengrui Medicine Recent Developments
  43. 7.8 Fresenius Kabi
  44. 7.8.1 Fresenius Kabi Company Information
  45. 7.8.2 Fresenius Kabi Business Overview
  46. 7.8.3 Fresenius Kabi Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Fresenius Kabi Long-acting rhG-CSF Product Portfolio
  48. 7.8.5 Fresenius Kabi Recent Developments
  49. 7.9 Amgen Inc.
  50. 7.9.1 Amgen Inc. Company Information
  51. 7.9.2 Amgen Inc. Business Overview
  52. 7.9.3 Amgen Inc. Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Amgen Inc. Long-acting rhG-CSF Product Portfolio
  54. 7.9.5 Amgen Inc. Recent Developments
  55. 7.10 Spectrum Pharmaceuticals
  56. 7.10.1 Spectrum Pharmaceuticals Company Information
  57. 7.10.2 Spectrum Pharmaceuticals Business Overview
  58. 7.10.3 Spectrum Pharmaceuticals Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Spectrum Pharmaceuticals Long-acting rhG-CSF Product Portfolio
  60. 7.10.5 Spectrum Pharmaceuticals Recent Developments
  61. 7.11 Coherus BioSciences, Inc.
  62. 7.11.1 Coherus BioSciences, Inc. Company Information
  63. 7.11.2 Coherus BioSciences, Inc. Business Overview
  64. 7.11.3 Coherus BioSciences, Inc. Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Coherus BioSciences, Inc. Long-acting rhG-CSF Product Portfolio
  66. 7.11.5 Coherus BioSciences, Inc. Recent Developments
  67. 7.12 Biocon Biologics Inc.
  68. 7.12.1 Biocon Biologics Inc. Company Information
  69. 7.12.2 Biocon Biologics Inc. Business Overview
  70. 7.12.3 Biocon Biologics Inc. Long-acting rhG-CSF Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Biocon Biologics Inc. Long-acting rhG-CSF Product Portfolio
  72. 7.12.5 Biocon Biologics Inc. Recent Developments
8 North America
  1. 8.1 North America Long-acting rhG-CSF Market Size by Type
  2. 8.1.1 North America Long-acting rhG-CSF Revenue by Type (2021-2032)
  3. 8.1.2 North America Long-acting rhG-CSF Sales by Type (2021-2032)
  4. 8.1.3 North America Long-acting rhG-CSF Price by Type (2021-2032)
  5. 8.2 North America Long-acting rhG-CSF Market Size by Application
  6. 8.2.1 North America Long-acting rhG-CSF Revenue by Application (2021-2032)
  7. 8.2.2 North America Long-acting rhG-CSF Sales by Application (2021-2032)
  8. 8.2.3 North America Long-acting rhG-CSF Price by Application (2021-2032)
  9. 8.3 North America Long-acting rhG-CSF Market Size by Country
  10. 8.3.1 North America Long-acting rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Long-acting rhG-CSF Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Long-acting rhG-CSF Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Long-acting rhG-CSF Market Size by Type
  2. 9.1.1 Europe Long-acting rhG-CSF Revenue by Type (2021-2032)
  3. 9.1.2 Europe Long-acting rhG-CSF Sales by Type (2021-2032)
  4. 9.1.3 Europe Long-acting rhG-CSF Price by Type (2021-2032)
  5. 9.2 Europe Long-acting rhG-CSF Market Size by Application
  6. 9.2.1 Europe Long-acting rhG-CSF Revenue by Application (2021-2032)
  7. 9.2.2 Europe Long-acting rhG-CSF Sales by Application (2021-2032)
  8. 9.2.3 Europe Long-acting rhG-CSF Price by Application (2021-2032)
  9. 9.3 Europe Long-acting rhG-CSF Market Size by Country
  10. 9.3.1 Europe Long-acting rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Long-acting rhG-CSF Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Long-acting rhG-CSF Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Long-acting rhG-CSF Market Size by Type
  2. 10.1.1 China Long-acting rhG-CSF Revenue by Type (2021-2032)
  3. 10.1.2 China Long-acting rhG-CSF Sales by Type (2021-2032)
  4. 10.1.3 China Long-acting rhG-CSF Price by Type (2021-2032)
  5. 10.2 China Long-acting rhG-CSF Market Size by Application
  6. 10.2.1 China Long-acting rhG-CSF Revenue by Application (2021-2032)
  7. 10.2.2 China Long-acting rhG-CSF Sales by Application (2021-2032)
  8. 10.2.3 China Long-acting rhG-CSF Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Long-acting rhG-CSF Market Size by Type
  2. 11.1.1 Asia Long-acting rhG-CSF Revenue by Type (2021-2032)
  3. 11.1.2 Asia Long-acting rhG-CSF Sales by Type (2021-2032)
  4. 11.1.3 Asia Long-acting rhG-CSF Price by Type (2021-2032)
  5. 11.2 Asia Long-acting rhG-CSF Market Size by Application
  6. 11.2.1 Asia Long-acting rhG-CSF Revenue by Application (2021-2032)
  7. 11.2.2 Asia Long-acting rhG-CSF Sales by Application (2021-2032)
  8. 11.2.3 Asia Long-acting rhG-CSF Price by Application (2021-2032)
  9. 11.3 Asia Long-acting rhG-CSF Market Size by Country
  10. 11.3.1 Asia Long-acting rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Long-acting rhG-CSF Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Long-acting rhG-CSF Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Long-acting rhG-CSF Market Size by Type
  2. 12.1.1 SAMEA Long-acting rhG-CSF Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Long-acting rhG-CSF Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Long-acting rhG-CSF Price by Type (2021-2032)
  5. 12.2 SAMEA Long-acting rhG-CSF Market Size by Application
  6. 12.2.1 SAMEA Long-acting rhG-CSF Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Long-acting rhG-CSF Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Long-acting rhG-CSF Price by Application (2021-2032)
  9. 12.3 SAMEA Long-acting rhG-CSF Market Size by Country
  10. 12.3.1 SAMEA Long-acting rhG-CSF Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Long-acting rhG-CSF Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Long-acting rhG-CSF Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Long-acting rhG-CSF Value Chain Analysis
  2. 13.1.1 Long-acting rhG-CSF Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Long-acting rhG-CSF Production Mode & Process
  6. 13.2 Long-acting rhG-CSF Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Long-acting rhG-CSF Distributors
  9. 13.2.3 Long-acting rhG-CSF Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst